Long Term Debt Summary of Arch Biopartners Inc.

Arch Biopartners Inc.'s latest annual long term debt in 2023 was 703.92 Thousand CAD , down -69.56% from previous year.
Arch Biopartners Inc.'s latest quarterly long term debt in 2024 Q3 was 500 Thousand CAD , down 0.0% from previous quarter.
Arch Biopartners Inc. reported annual long term debt of 2.31 Million CAD in 2022, down -31.2% from previous year.
Arch Biopartners Inc. reported annual long term debt of 3.36 Million CAD in 2021, down -0.85% from previous year.
Arch Biopartners Inc. reported quarterly long term debt of 500 Thousand CAD for 2024 Q3, down 0.0% from previous quarter.
Arch Biopartners Inc. reported quarterly long term debt of 500 Thousand CAD for 2024 Q1, down -28.97% from previous quarter.

Annual Long Term Debt Chart of Arch Biopartners Inc. (2023 - 1997)

Historical Annual Long Term Debt of Arch Biopartners Inc. (2023 - 1997)

Year	Long Term Debt	Long Term Debt Growth
2023	703.92 Thousand CAD	-69.56%
2022	2.31 Million CAD	-31.2%
2021	3.36 Million CAD	-0.85%
2020	3.39 Million CAD	17.51%
2019	2.88 Million CAD	94.51%
2018	1.48 Million CAD	324.46%
2017	349.44 Thousand CAD	5.82%
2016	330.21 Thousand CAD	0.59%
2015	328.27 Thousand CAD	0.0%
2014	- CAD	0.0%
2013	- CAD	0.0%
2012	- CAD	0.0%
2011	- CAD	0.0%
2010	- CAD	0.0%
2009	- CAD	0.0%
2008	- CAD	0.0%
2007	- CAD	0.0%
2006	- CAD	-100.0%
2005	1661.00 CAD	-80.53%
2004	8533.00 CAD	-91.22%
2003	97.23 Thousand CAD	-31.47%
2002	141.89 Thousand CAD	0.0%
2001	- CAD	0.0%
2000	- CAD	0.0%
1999	- CAD	0.0%
1998	- CAD	0.0%
1997	- CAD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q2	500 Thousand CAD	0.0%
2024 Q3	500 Thousand CAD	0.0%
2024 Q1	500 Thousand CAD	-28.97%
2023 FY	703.92 Thousand CAD	-69.56%
2023 Q4	703.92 Thousand CAD	-75.54%
2023 Q1	2.29 Million CAD	-0.93%
2023 Q3	2.87 Million CAD	24.27%
2023 Q2	2.31 Million CAD	1.08%
2022 Q1	3.36 Million CAD	-0.01%
2022 FY	2.31 Million CAD	-31.2%
2022 Q4	2.31 Million CAD	-31.18%
2022 Q2	3.36 Million CAD	-0.01%
2022 Q3	3.36 Million CAD	-0.01%
2021 Q2	3.39 Million CAD	0.01%
2021 Q3	3.39 Million CAD	-0.01%
2021 Q4	3.36 Million CAD	-0.86%
2021 FY	3.36 Million CAD	-0.85%
2021 Q1	3.39 Million CAD	0.01%
2020 Q3	3.39 Million CAD	0.13%
2020 Q4	3.39 Million CAD	-0.23%
2020 FY	3.39 Million CAD	17.51%
2020 Q2	3.39 Million CAD	17.46%
2020 Q1	2.88 Million CAD	0.15%
2019 Q2	1.94 Million CAD	34.22%
2019 Q1	1.44 Million CAD	-2.55%
2019 Q3	2.94 Million CAD	51.81%
2019 Q4	2.88 Million CAD	-2.04%
2019 FY	2.88 Million CAD	94.51%
2018 Q3	1.46 Million CAD	0.96%
2018 FY	1.48 Million CAD	324.46%
2018 Q4	1.48 Million CAD	1.31%
2018 Q2	1.45 Million CAD	70.68%
2018 Q1	849.61 Thousand CAD	143.13%
2017 Q4	349.44 Thousand CAD	9.24%
2017 FY	349.44 Thousand CAD	5.82%
2017 Q1	334.16 Thousand CAD	1.19%
2017 Q2	334.19 Thousand CAD	0.01%
2017 Q3	319.88 Thousand CAD	-4.28%
2016 FY	330.21 Thousand CAD	0.59%
2016 Q4	330.21 Thousand CAD	-0.79%
2016 Q2	338.2 Thousand CAD	1.5%
2016 Q1	333.2 Thousand CAD	1.5%
2016 Q3	332.83 Thousand CAD	-1.59%
2015 Q2	317.39 Thousand CAD	0.0%
2015 Q1	- CAD	0.0%
2015 Q4	328.27 Thousand CAD	2.09%
2015 FY	328.27 Thousand CAD	0.0%
2015 Q3	321.54 Thousand CAD	1.31%
2014 FY	- CAD	0.0%
2014 Q4	- CAD	0.0%
2014 Q3	- CAD	0.0%
2014 Q1	- CAD	0.0%
2014 Q2	- CAD	0.0%
2013 Q3	- CAD	0.0%
2013 Q4	- CAD	0.0%
2013 Q1	- CAD	0.0%
2013 Q2	- CAD	0.0%
2013 FY	- CAD	0.0%
2012 Q4	- CAD	0.0%
2012 Q1	- CAD	0.0%
2012 Q2	- CAD	0.0%
2012 Q3	- CAD	0.0%
2012 FY	- CAD	0.0%
2011 FY	- CAD	0.0%
2011 Q4	- CAD	0.0%
2011 Q3	- CAD	0.0%
2011 Q2	- CAD	0.0%
2011 Q1	- CAD	0.0%
2010 Q2	- CAD	0.0%
2010 FY	- CAD	0.0%
2010 Q1	- CAD	0.0%
2010 Q3	- CAD	0.0%
2010 Q4	- CAD	0.0%
2009 Q4	- CAD	0.0%
2009 FY	- CAD	0.0%
2009 Q1	- CAD	0.0%
2009 Q2	- CAD	0.0%
2009 Q3	- CAD	0.0%
2008 Q4	- CAD	0.0%
2008 Q1	- CAD	0.0%
2008 Q2	- CAD	0.0%
2008 FY	- CAD	0.0%
2008 Q3	- CAD	0.0%
2007 FY	- CAD	0.0%
2007 Q4	- CAD	0.0%
2007 Q3	- CAD	0.0%
2007 Q2	- CAD	0.0%
2007 Q1	- CAD	-100.0%
2006 FY	- CAD	-100.0%
2006 Q4	1706.00 CAD	-0.47%
2006 Q3	1714.00 CAD	0.53%
2006 Q2	1705.00 CAD	2.65%
2006 Q1	1661.00 CAD	0.0%
2005 Q4	- CAD	-100.0%
2005 Q2	5093.00 CAD	-40.31%
2005 Q1	8533.00 CAD	-95.83%
2005 FY	1661.00 CAD	-80.53%
2005 Q3	3628.00 CAD	-28.76%
2004 Q2	91.42 Thousand CAD	-5.97%
2004 Q1	97.23 Thousand CAD	0.0%
2004 FY	8533.00 CAD	-91.22%
2004 Q4	204.39 Thousand CAD	-27.89%
2004 Q3	283.45 Thousand CAD	210.03%
2003 Q4	- CAD	0.0%
2003 FY	97.23 Thousand CAD	-31.47%
2003 Q1	141.89 Thousand CAD	0.0%
2003 Q2	- CAD	-100.0%
2003 Q3	- CAD	0.0%
2002 Q1	- CAD	0.0%
2002 Q4	- CAD	0.0%
2002 FY	141.89 Thousand CAD	0.0%
2002 Q3	- CAD	0.0%
2002 Q2	- CAD	0.0%
2001 Q2	- CAD	0.0%
2001 Q3	- CAD	0.0%
2001 FY	- CAD	0.0%
2001 Q1	- CAD	0.0%
2000 Q1	- CAD	0.0%
2000 FY	- CAD	0.0%
1999 FY	- CAD	0.0%
1999 Q1	- CAD	0.0%
1998 Q3	- CAD	0.0%
1998 Q2	- CAD	0.0%
1998 FY	- CAD	0.0%
1998 Q4	- CAD	0.0%
1997 FY	- CAD	0.0%

Peer Long Term Debt Comparison of Arch Biopartners Inc.

Name	Long Term Debt	Long Term Debt Difference
Eiger BioPharmaceuticals, Inc.	- USD	-Infinity%
Nanobac Pharmaceuticals, Incorporated	- USD	-Infinity%
SQZ Biotechnologies Company	20.9 Million USD	96.633%
Evofem Biosciences, Inc.	8000.00 USD	-8699.013%
Santhera Pharmaceuticals Holding AG	1.75 Million USD	59.901%
Mesoblast Limited	100.29 Million USD	99.298%
Propanc Biopharma, Inc.	58.64 Thousand USD	-1100.37%
Genus plc	228.2 Million USD	99.692%
VioQuest Pharmaceuticals, Inc.	- USD	-Infinity%
CNBX Pharmaceuticals Inc.	- USD	-Infinity%
Marizyme, Inc.	667.12 Thousand USD	-5.515%
ContraFect Corporation	2.21 Million USD	68.148%
Nymox Pharmaceutical Corporation	- USD	-Infinity%
PsyBio Therapeutics Corp.	- USD	-Infinity%
Sienna Biopharmaceuticals, Inc.	- USD	-Infinity%
RegeneRx Biopharmaceuticals, Inc.	1.4 Million USD	49.825%
Intellipharmaceutics International Inc.	- USD	-Infinity%
AXIM Biotechnologies, Inc.	5.42 Million USD	87.028%
MultiCell Technologies, Inc.	36.43 USD	-1932156.382%
Accustem Sciences Inc.	- USD	-Infinity%
RVL Pharmaceuticals plc	55.61 Million USD	98.734%
EV Biologics, Inc.	- USD	-Infinity%
Q BioMed Inc.	- USD	-Infinity%
Emmaus Life Sciences, Inc.	2.22 Million USD	68.377%
Neon Bloom, Inc.	- USD	-Infinity%
Mosaic ImmunoEngineering Inc.	1.22 Million USD	42.694%
Biomind Labs Inc.	- USD	-Infinity%
TetraLogic Pharmaceuticals Corporation	- USD	-Infinity%
Pharming Group N.V.	166.1 Million USD	99.576%
Oncotelic Therapeutics, Inc.	1.89 Million USD	62.922%
Skye Bioscience, Inc.	171.23 Thousand USD	-311.097%
Therapeutic Solutions International, Inc.	5512.00 USD	-12670.7%
THC Farmaceuticals, Inc.	- USD	-Infinity%
Arch Therapeutics, Inc.	- USD	-Infinity%
IMV Inc.	27.39 Million USD	97.431%
Acro Biomedical Co., Ltd.	- USD	-Infinity%
Curative Biotechnology, Inc.	- USD	-Infinity%
GB Sciences, Inc.	322 Thousand USD	-118.609%
Alpha Cognition Inc.	- USD	-Infinity%
HST Global, Inc.	- USD	-Infinity%
CSL Limited	11.23 Billion USD	99.994%
Halberd Corporation	150 Thousand USD	-369.281%
Enzolytics Inc.	- USD	-Infinity%
Resverlogix Corp.	- USD	-Infinity%
Affymax, Inc.	- USD	-Infinity%
SYBLEU INC	300 Thousand USD	-134.64%
Nuo Therapeutics, Inc.	164.2 Thousand USD	-328.684%
argenx SE	15.35 Million USD	95.415%
MetaStat, Inc.	- USD	-Infinity%
Northwest Biotherapeutics, Inc.	20.31 Million USD	96.534%
Enzon Pharmaceuticals, Inc.	- USD	-Infinity%
Arno Therapeutics, Inc.	- USD	-Infinity%
RespireRx Pharmaceuticals Inc.	- USD	-Infinity%
GeneThera, Inc.	- USD	-Infinity%
Inhibitor Therapeutics, Inc.	- USD	-Infinity%
AVAX Technologies, Inc.	- USD	-Infinity%
Zenith Capital Corp.	4456.00 USD	-15697.15%
Genscript Biotech Corporation	287.12 Million USD	99.755%
Ember Therapeutics, Inc.	- USD	-Infinity%
Anthera Pharmaceuticals, Inc.	- USD	-Infinity%
Sigyn Therapeutics, Inc.	126.3 Thousand USD	-457.332%
WPD Pharmaceuticals Inc.	229.29 Thousand USD	-206.999%
American Oriental Bioengineering, Inc.	554.59 Thousand USD	-26.926%
Provectus Biopharmaceuticals, Inc.	25.29 Thousand USD	-2682.406%
Adynxx, Inc.	- USD	-Infinity%
Helix BioMedix, Inc.	- USD	-Infinity%
GlobeStar Therapeutics Corporation	- USD	-Infinity%
VitaSpring Biomedical Co. Ltd.	- USD	-Infinity%
Capstone Therapeutics Corp.	8.26 Million USD	91.482%
Cotinga Pharmaceuticals Inc.	- USD	-Infinity%
BioStem Technologies, Inc.	265.63 Thousand USD	-164.996%
ONE Bio Corp.	592.19 Thousand USD	-18.866%
Reve Technologies, Inc.	1064.00 USD	-66057.989%
Burzynski Research Institute, Inc.	- USD	-Infinity%
Wesana Health Holdings Inc.	- USD	-Infinity%
Agentix Corp.	- USD	-Infinity%
LadRx Corporation	- USD	-Infinity%
Cell Source, Inc.	- USD	-Infinity%
ProtoKinetix, Incorporated	- USD	-Infinity%
Regen BioPharma, Inc.	149.61 Thousand USD	-370.491%
Regen BioPharma, Inc.	149.61 Thousand USD	-370.491%
NovAccess Global Inc.	- USD	-Infinity%
Endonovo Therapeutics, Inc.	- USD	-Infinity%
Itoco Inc.	- USD	-Infinity%
Rasna Therapeutics, Inc.	- USD	-Infinity%
Pathfinder Cell Therapy, Inc.	- USD	-Infinity%
Kadimastem Ltd	229.69 Thousand USD	-206.464%
Oncology Pharma Inc.	- USD	-Infinity%
Institute of Biomedical Research Corp.	- USD	-Infinity%
CytoDyn Inc.	141 Thousand USD	-399.235%
Claritas Pharmaceuticals, Inc.	- USD	-Infinity%
NDT Pharmaceuticals Inc.	- USD	-Infinity%
Mobile Lads Corp.	- USD	-Infinity%
NanoSphere Health Sciences Inc.	- USD	-Infinity%
Qrons Inc.	80 Thousand USD	-779.901%
Alseres Pharmaceuticals, Inc.	7.81 Million USD	90.998%
Advanced Proteome Therapeutics Corporation	- USD	-Infinity%
Nascent Biotech, Inc.	- USD	-Infinity%
Rebus Holdings, Inc.	- USD	-Infinity%
ImmunoCellular Therapeutics, Ltd.	369.04 Thousand USD	-90.739%
International Stem Cell Corporation	445 Thousand USD	-58.184%
Bioxytran, Inc.	- USD	-Infinity%
GlobeImmune, Inc.	- USD	-Infinity%
Predictive Technology Group, Inc.	- USD	-Infinity%
ProText Mobility, Inc.	- USD	-Infinity%
Cardax, Inc.	- USD	-Infinity%
VG Life Sciences Inc.	- USD	-Infinity%
Kaleido Biosciences, Inc.	- USD	-Infinity%
Advaxis, Inc.	8.15 Million USD	91.363%
Adhera Therapeutics, Inc.	- USD	-Infinity%
RenovaCare, Inc.	- USD	-Infinity%
Regnum Corp.	- USD	-Infinity%
Innovation Pharmaceuticals Inc.	457 Thousand USD	-54.031%
Neutra Corp.	- USD	-Infinity%
Windtree Therapeutics, Inc.	1.16 Million USD	39.369%
PureTech Health plc	18.25 Million USD	96.143%
Coeptis Therapeutics, Inc.	150 Thousand USD	-369.281%
IXICO plc	275 Thousand USD	-155.971%
IntelGenx Technologies Corp.	11.83 Million USD	94.054%
Gelesis Holdings, Inc.	26.3 Million USD	97.324%
CSL Limited	11.23 Billion USD	99.994%
Cellectis S.A.	36.21 Million USD	98.056%

Global Stocks Search

Arch Biopartners Inc. (ACHFF)

Long Term Debt Summary of Arch Biopartners Inc.

Annual Long Term Debt Chart of Arch Biopartners Inc. (2023 - 1997)

Historical Annual Long Term Debt of Arch Biopartners Inc. (2023 - 1997)

Peer Long Term Debt Comparison of Arch Biopartners Inc.